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Cell cycle progression is governed by several checkpoints, which
are regulated by a family of protein kinases, the cyclin-dependent
kinases (CDKs) and the cyclins (Hunter and Pines, 1994). The
restriction point is one of the most important checkpoints in the
late G1 phase. Disruption of the checkpoints is one mechanism of
oncogenesis. p21WAF1/CIP1 protein, a universal CDK inhibitor
(Xiong et al, 1993), and p53 protein are two important components
of the G1 restriction point.
Recently, the p21WAF1/CIP1 gene was cloned and mapped to the
6p21.2 chromosome region (El-Deiry et al, 1993; Noda et al,
1994). p21WAF1/CIP1 inhibits a wide variety of cyclin–CDK complex
activities by binding to the complexes (Harper et al, 1993; Xiong
et al, 1993). p21WAF1/CIP1 has also recently been shown to bind to
and inactivate proliferation cell nuclear antigen, the processivity
subunit of DNA polymerase d (Waga et al, 1994). These observa-
tions suggest that p21WAF1/CIP1 may play a dual role in blocking
entry into S phase (Noda et al, 1994). In addition, p21WAF1/CIP1 has
also been suggested to play a role in inducing differentiation and
apoptosis (Michieli et al, 1994; Sheikh et al, 1995), and introduc-
tion of p21WAF1/CIP1 cDNA suppresses the growth of human tumour
cells in culture (El-Deiry et al, 1993).
Cells lacking functional p53 express a very low level of
p21WAF1/CIP1 and the p21WAF1/CIP1 promoter contains a p53-binding
site, suggesting that expression of p21WAF1/CIP1 depends on p53
function (El-Deiry et al, 1993, 1994; Xiong et al, 1993). However,
p21WAF1/CIP1 can be inducible in p53-null cells, showing that the
expression of p21WAF1/CIP1 can also be induced by p53-independent
pathways (Michieli et al, 1994; Zhang et al, 1995).
We previously investigated p21WAF1/CIP1 mRNA expression by
reverse-transcriptase polymerase chain reaction (RT-PCR) and
p53 mutational status by PCR single-strand conformation poly-
morphism (SSCP) and direct DNA sequencing in hepatocellular
carcinomas (HCCs). We suggested that p21WAF1/CIP1 mRNA expres-
sion is regulated predominantly by a p53-dependent pathway and
that reduced p21WAF1/CIP1 mRNA expression may contribute to
hepatocarcinogenesis (Hui et al, 1997). However, we did not eval-
uate the expression of p21WAF1/CIP1 and p53 at the protein level.
Because post-transcriptional regulation is also an important mech-
anism in gene expression (Hui et al, 1996b; Loda et al, 1997; Maki
and Howley, 1997), and loss of function of p53 is caused not only
by gene mutation but also when p53 protein interacts with viral or
cellular oncoproteins (Sarnow et al, 1982; Farmer et al, 1992; Yew
and Berk, 1992; Steegenga et al, 1996; Somasundaram and El-
Deiry, 1997), it is necessary to investigate p21WAF1/CIP1 and p53 at
the protein level. The wild-type p53 protein has a short half-life of
about 20 min, and in general it cannot be detected by immuno-
histochemistry. However, a p53 gene mutation or p53 interacting
with oncoproteins may stabilize p53 protein and result in altered
expression of p53 that can be detected by immunohistochemistry
(Sarnow et al, 1982; Finlay et al, 1988; Iggo et al, 1990; Hall et al,
1991; Farmer et al, 1992; Yew and Berk, 1992; Steegenga et al,
1996; Somasundaram and El-Deiry, 1997).
We investigated the expression of p21WAF1/CIP1 and p53 proteins
in 81 tumours from 65 patients with HCC by immunostaining
to determine whether p21WAF1/CIP1 expression depends on p53
functional status, and the relationship between the two proteins’
expression and clinicopathological features.
Reduced p21WAF1/CIP1 protein expression is predominantly
related to altered p53 in hepatocellular carcinomas
Y-Z Shi, A-M Hui, T Takayama, X Li, X Cui and M Makuuchi
Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo0ku,
Tokyo 113-0033, Japan
Summary To investigate the relationship between the expression of p21WAF1/ClP1 protein and p53 status and the possible role of the two
proteins in hepatocellular carcinomas (HCCs), we examined the expression of p21WAF1/CIP1 and p53 immunohistochemically in 81 tumours
from 65 patients with hepatocellular carcinoma. p21WAF1/CIP1 protein was absent from 59 of 81 tumours (72.8%), and altered p53 expression
was found in 43 (53.1%). p21WAF1/CIP1 expression was significantly associated with p53 status (P = 0.0008); 38 of 59 tumours lacking
p21WAF1/CIP1 protein were accompanied by altered p53 expression. Further analyses showed that p21WAF1/CIP1 expression was inversely
correlated with p53 expression in hepatitis C virus (HCV)-related HCCs, but not in HBV-related hepatocellular carcinomas and hepatocellular
carcinomas without viral infection. All 11 tumours with intrahepatic metastasis showed altered p21WAF1/CIP1 or p53 expression. In contrast, no
intrahepatic metastasis was found in any of the 17 tumours without abnormal expression of either of the two proteins. These results suggest
that: (1) different modes of p21WAF1/CIP1 regulation are involved in HCCs differing in their hepatitis viral infection status, and p21WAF1/CIP1
expression appears to be predominantly related to altered p53 in HCV-related HCCs; (2) disruption of the p53–p21WAF1/CIP1 cell-
cycle-regulating pathway may contribute to malignant progression of HCC. © 2000 Cancer Research Campaign
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Patients and specimens
Eighty-one primary HCC tissues were obtained from 65 patients
who underwent surgical resection at the Hepato-Biliary-Pancreatic
Surgery Division, Department of Surgery, Graduate School of
Medicine, University of Tokyo, Tokyo, Japan. Fifty patients were
found to have underlying cirrhosis, and 15 had chronic hepatitis.
The study included 13 (20%) women and 52 (80%) men with a
mean age of 61 years (range 13–74 years). Fifty-six patients had
serological evidence of viral infection (11 were positive for
hepatitis B surface antigen [HBsAg], 43 were positive for hepatitis
C virus [HCV] antibody and two were positive for both markers).
The remaining nine patients were negative for both hepatitis
markers. Tissue samples were obtained at the time of operation,
fixed in 10% formalin, and histopathologically examined. The size
of the tumours varied from 0.6 to 15 cm (mean 4.0 ± 3.5 s.d.). The
81 tumours comprised 23 well-, 43 moderately, and 15 poorly
differentiated HCCs. Portal vein tumour thrombi were found in 18
(22.2%) HCCs, and intrahepatic metastatic lesions were found in
11 (13.6%).
Immunohistochemical staining for p21WAF1/CIP1 and p53
Immunohistochemistry was done using the avidin–biotin–peroxi-
dase complex method. Paraffin-embedded sections (4 mm-thick)
were deparaffinized in xylene, rehydrated in decreasing concentra-
tions of ethanol and then treated with 3% hydrogen peroxide in
methanol for 30 min to block endogenous peroxidase activity.
After brief washing with distilled water, tissue sections were
processed in 10 mM citrate buffer (pH 6.0) and heated to 120°C in
an autoclave for 10 min for antigen retrieval (Hui et al, 1999a,
1999b, 2000; Li et al, 2000). Slides were allowed to cool at room
temperature for 20 min and then rinsed with phosphate-buffered
saline (PBS). To inhibit non-specific binding activity, slides were
incubated with blocking serum at room temperature for 30 min.
Sections then were incubated with primary monoclonal antibody
against p21WAF1/CIP1 (clone EA10, Oncogene Science, Cambridge,
MA, USA) diluted at 1:200, or with monoclonal antibody against
p53 (clone DO-7; Dako A/S, Denmark) at 1:100, at 4°C in a moist
chamber overnight. The sections were then incubated with
biotinylated anti-mouse immunoglobulins (Vector Laboratories,
Inc., Burlingame, CA, USA) for 30 min, and avidin–biotin
complex (Vector Laboratories) for 30 min at room temperature,
with washing in PBS before each incubation. 3,3¢-
Diaminobenzidine tetrahydrochloride was used as the colour
reagent, and haematoxylin was used as a counterstain. Normal
oesophageal squamous epithelium and HCC with known p53 gene
mutation and p53 protein overexpression were used as positive
controls for p21WAF1/CIP1 and p53 respectively. Negative controls
were obtained by omitting primary antibody. Only nuclear staining
was considered to be positive for p21WAF1/CIP1 and p53. Based on
p21WAF1/CIP1 and p53 in hepatocellular carcinomas 51
British Journal of Cancer (2000) 83(1), 50–55 © 2000 Cancer Research Campaign
AB
CD
Figure 1 Representative examples of immunohistochemical staining of p21WAF1/CIP1 and p53. Tumour shows positive nuclear staining for p21WAF1/CIP1 (A) while
not for p53 (B). Tumour is completely negative for p21WAF1/CIP1 (C), while p53 is diffusely stained (D). (´ 350)the previously published criteria, positive staining of p21WAF1/CIP1
was considered when ³ 5% of tumour cells were stained (Ogawa et
al, 1997). Positive scoring for p53 was considered when ³ 10% of
the nuclei were stained, according to the criteria used previously
(Esrig et al, 1994; Cote et al, 1998).
Statistical analysis
c2 test or Fisher’s exact test was used to examine differences and
relationships between groups of patients classified by p21WAF1/CIP1
and p53 staining. Differences at P < 0.05 were judged to be
statistically significant.
RESULTS
p21WAF1/CIP1 expression
p21WAF1/CIP1 immunoreactivity was always nuclear, and no cyto-
plasmic staining of p21WAF1/CIP1 was seen in any specimen. The
HCCs showed heterogeneous expression of p21WAF1/CIP1; the
percentage of p21WAF1/CIP1-positive cells ranged from 0% to 60%
(median 5%). Twenty-two of 81 HCCs (27.2%) showed positive
staining for p21WAF1/CIP1 protein (Figure 1A). Most (86.4%)
p21WAF1/CIP1-negative tumours showed < 1% positive cells or
complete loss of immunoreactivity. p21WAF1/CIP1 expression was
not associated with viral infection, histological features of non-
tumourous livers, tumour size, tumour differentiation, intrahepatic
metastasis, or tumour portal or hepatic vein involvement
(P > 0.05; Table 1).
p53 expression
Forty-three of 81 HCCs (53.1%) showed positive staining for p53
protein (Figure 1D). No positive p53 expression was observed in
the corresponding non-tumourous liver tissue. p53 overexpression
was more frequent in moderately differentiated tumours (23/43
HCCs, 53.5%) than in well-differentiated tumours (8/23 HCCs,
34.8%), and was even more frequent in poorly differentiated
tumours (12/15 HCCs, 80%) (poorly vs well-differentiated, P =
0.0064; Table 1). A trend approaching significance was observed
between positive p53 expression and tumour portal vein invasion
(P = 0.06; Table 1). No association was found between positive
p53 expression and any other clinicopathological parameters
examined.
Relationship between p21WAF1/CIP1 and p53 expression
The expression of p21WAF1/CIP1 was significantly associated with
p53 status (P = 0.0008, Table 2); 38 of the 43 tumours (88.4%)
with aberrant p53 expression showed loss of p21WAF1/CIP1 expres-
sion and 38 of the 59 tumours (64.4%) without p21WAF1/CIP1 expres-
sion were accompanied by altered p53 expression (two tumours
showing an inverse staining pattern of p21WAF1/CIP1 and p53 are
shown in Figure 1 A–D). However, 21 of the 59 (35.6%) tumours
lacking p21WAF1/CIP1 protein showed p53-negative staining, and
five tumours showed concurrent positive staining of p21WAF1/CIP1
and p53.
The relationship between p21WAF1/CIP1 and p53 expression was
further evaluated in HCV-related HCCs, HBV-related HCCs and
HCCs with no virus infection (Table 2). The expression of
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Table 1 Relationship between p21WAF1/CIP1 and p53 protein expression and clinicopathological features in HCCs
Clinicopathology p21WAF1/CIP1 (–) P-value p53 (+) P-value
Virus infectiona
HBV 11/13 (84.6%) 0.39 5/13 (38.5%) 0.71
HCV 37/54 (68.5%) 30/54 (55.6%)
HBV + HCV 3/5 (60.0%) 3/5 (60.0%)
Negative 8/9 (88.9%) 5/9 (55.6%)
Background liver disease
Chronic hepatitis 15/18 (83.3%) 0.46 9/18 (50.0%) 0.85
Liver cirrhosis 44/63 (69.8%) 34/63 (54.0%)
Tumour size (cm)
<2 21/29 (72.4%) 0.52 15/29 (51.7%) 0.73
2–5 23/29 (79.3%) 17/29 (58.6%)
³5 15/23 (65.2%) 11/23 (47.8%)
Tumour differentiation
Well 15/23 (65.2%) 0.40 8/23 (34.8%) *
Moderate 34/43 (79.1%) 23/43 (53.5%) **
Poor 10/15 (66.7%) 12/15 (80.0%)
Intrahepatic metastasis
Positive 9/11 (81.8%) 0.47 7/11 (63.6%) 0.45
Negative 50/70 (71.4%) 36/70 (51.4%)
Portal involvement
Positive 12/18 (66.7%) 0.50 13/18 (72.2%) 0.06
Negative 47/63 (74.6%) 30/63 (47.6%)
Venous involvement
Positive 4/7 (57.1%) 0.33 4/7 (57.1%) 0.82
Negative 55/74 (74.3%) 39/74 (52.7%)
a HBV, HBsAg-positive; HCV, anti-HCV-antibody-positive; HBV + HCV, both markers positive; Negative, both markers negative. *Well vs poorly differentiated,
P = 0.0064; **Moderately vs poorly differentiated, P = 0.07.p21WAF1/CIP1 and p53 in hepatocellular carcinomas 53
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p21WAF1/CIP1 was significantly correlated with p53 expression in
HCV-related HCCs, but not in HBV-related HCCs or HCCs
without virus infection.
The tumours were divided into two groups based on the
expression patterns of the two proteins: I, p21WAF1/CIP1+/p53–
(17 HCCs; no abnormality in either protein); and II,
p21WAF1/CIP1+/p53+, p21WAF1/CIP1–/p53– or p21WAF1/CIP1–/p53+
(64 HCCs; at least one altered expression involved in the two
proteins). When this was done, a trend approaching significance
was observed between the two groups (P = 0.066); intrahepatic
metastasis was observed more frequently in group II (11/64,
17.2%) than in group I (0/17, 0%). There was no significant rela-
tionship between either group and any of the clinicopathological
features examined (P > 0.05).
DISCUSSION
p21WAF1/CIP1 plays a key role in p53-mediated arrest of the cell cycle
in response to DNA damage (E1-Deiry et al, 1993, 1994; Xiong
et al, 1993; Dulic et al, 1994). p21WAF1/CIP1 inhibits transition from
G1 to the S phase by inhibiting a wide variety of cyclin–CDK
complexes, including cyclin D–CDK4, cyclin D–CDK2, and
cyclin E–CDK2 (Gu et al, 1993; Harper et al, 1993; Xiong et al,
1993). Strikingly, in normal cells, p21WAF1/CIP1 is associated with
quaternary complexes of most cyclins, CDKs, and proliferation
cell nuclear antigens, but is absent from these complexes in most
transformed cells (Xiong et al, 1993). These observations suggest
that reduction or loss of p21WAF1/CIP1 expression plays an important
role in tumorigenesis. Our results showed that absence of
p21WAF1/CIP1 expression was very common (59/81; 72.8%) in
HCCs, suggesting that the absence of p21WAF1/CIP1 expression may
be involved in hepatocarcinogenesis.
There are several possible mechanisms that down-regulate
p21WAF1/CIP1 expression. First, the expression of p21WAF1/CIP1 is tran-
scriptionally induced by wild-type but not mutant p53 (El-Deiry
et al, 1993). We have shown previously that HCCs with wild-type
p53 express significantly greater p21WAF1/CIP1 mRNA than tumours
with mutant p53 (Hui et al, 1997). In the present study, absence of
p21WAF1/CIP1 protein was significantly associated with altered p53
expression (P = 0.0008). Drawing together the observations of our
present and previous (Hui et al, 1997) studies, we suggest that the
p53-dependent transcriptional pathway is the main mechanism
that regulates p21WAF1/CIP1 expression in HCCs.
Second, 21 of the 59 (35.6%) tumours lacking p21WAF1/CIP1
protein showed p53-negative staining. Considering that negative
immunoreactivity of p53 reflects functional p53, we hypothesize
that, in these cases, p21WAF1/CIP1 is probably down-regulated by
other factor(s). Recently, it has been reported that HCV core
protein suppresses the transcriptional activity of the p21WAF1/CIP1
promoter (Ray et al, 1998). In the present study, 59 (including five
HCCs positive for both HCV and HBV markers) of the 81 HCCs
were associated with HCV infection. Therefore, we consider it is
highly probable that HCV core protein down-regulates p21WAF1/CIP1
expression in HCV-related HCCs. In this study group, 13 patients
(20%) were HBsAg-positive. No direct evidence that HBV virus
represses p21WAF1/CIP1 promoter activity has been reported.
Third, proteins can be regulated at the post-transcriptional level.
Down-regulation of p21WAF1/CIP1 expression through degradation
by a ubiquitin-dependent proteolytic pathway has recently been
reported (Maki and Howley, 1997). Therefore, we suggest that
post-transcriptional regulation may be another mechanism that
down-regulates p21WAF1/CIP1 expression in HCCs. Drawing together
the results of our present and previous (Hui et al, 1997) studies, we
consider that the higher incidence of p21WAF1/CIP1 protein absence
(72.8%) than the incidence of reduced p21WAF1/CIP1 mRNA expres-
sion (38.1%) further supports this hypothesis. These observations
also suggest that analysis of p21WAF1/CIP1 status at the protein level
may be more sensitive than analysis at the mRNA level.
Fourth, a mutation rate of 5% in p21WAF1/CIP1 has been reported in
HCCs (Furutani et al, 1997), so mutation of p21WAF1/CIP1 may be a
possible mechanism leading to altered p21WAF1/CIP1 expression in a
small proportion of HCCs.
We found concurrent positive expression of p21WAF1/CIP1 and p53
in five HCCs. Because p53 overexpression is a hallmark of non-
functional p53, the expression of p21WAF1/CIP1 in these cases may be
induced by p53-independent pathways (Michieli et al, 1994;
Zhang et al, 1995).
Two previous studies have evaluated the relationship between
the expression of p21WAF1/CIP1 and p53 at the protein level in HCCs,
although the results were controversial (Qin et al, 1998; Naka et al,
Table 2 Relationship between p21WAF1/CIP1 and p53 expression in HCCs
No. p21WAF1/CIP1-positive p21WAF1/CIP1-negative P-value
All HCCs
p53-positive 43 5/43 (11.6%) 38/43 (88.4%)
p53-negative 38 17/38 (44.7%) 21/38 (55.3%) 0.0008
No. 81 22 59
HCV-related HCCs
p53-positive 30 4/30 (13.3%) 26/30 (86.7%)
p53-negative 24 13/24 (54.2%) 11/24 (45.8%) 0.0013
No. 54 17 37
HBV-related HCCs
p53-positive 5 1/5 (20.0%) 4/5 (80.0%)
p53-negative 8 1/8 (12.5%) 7/8 (87.5%) 0.72
No. 13 2 11
HCCs with no hepatitis virus infection
p53-positive 5 0/5 (0%) 5/5 (100%)
p53-negative 4 1/4 (25.0%) 3/4 (75.0%) 0.24
No. 9 1 8
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1998). Naka et al demonstrated a significant inverse correlation
between expression of the two proteins, whereas Qin et al did not.
This discrepancy may be due to the difference in hepatitis viral
infection status between the two groups of patients, since the
molecular basis underlying HCV-related and HBV-related HCCs
appears to differ, at least partially. In Qin’s group (Chinese
patients), the majority (81/97, 84%) of the HCCs were HBV-
related, and a small subset (16/97, 16%) were HBsAg-negative.
No information about HCV infection was given for this group. On
the other hand, in Naka’s group (Japanese patients), 38% of HCCs
were HBV-related, 44% were HCV-related, and 18% had no
hepatitis virus infection. In both of these studies, the relationship
between p21WAF1/CIP1 and p53 expression in HBV-related HCCs or
HCV-related HCCs or HCCs without viral infection was not
studied separately. In contrast to the situation in China, the
majority (more than 65%) of HCCs in Japan are associated with
HCV, and only a small portion (10–15%) are caused by HBV
infection (Okuda, 1997). In our study group, 54 of the 81 HCCs
(67%) were HCV-related. We found that there was an inverse rela-
tionship between p21WAF1/CIP1 and p53 expression in HCV-related
HCCs, but failed to establish such a relationship in HBV-related
HCCs or HCCs without viral infection, suggesting that different
modes of p21WAF1/CIP1 regulation are involved in HCCs differing in
their hepatitis viral infection status. Our data are generally consis-
tent with the results of Qin et al and Naka et al, and offer a credible
explanation for the discrepancy between the conclusions of the
above two studies.
We found that p53 overexpression was significantly associated
with poor tumour differentiation. This is consistent with results of
a previous study of p53 in HCCs (Ng et al, 1995). We also found
that p53 overexpression was more frequent in tumours with portal
vein invasion than in tumours without. These observations suggest
that altered p53 may be involved in the progression of HCCs.
Increased p21WAF1/CIP1 mRNA levels can make metastatic human
melanoma cells lose their metastatic potential (Jiang et al, 1995).
We found a tendency for a relatively higher rate of p21WAF1/CIP1
expression in the group without intrahepatic metastasis than in the
group with intrahepatic metastasis, indicating a potential role of
p21WAF1/CIP1 dysfunction in the process of HCC metastasis. A corre-
lation between loss of p21WAF1/CIP1 expression and tumour meta-
stasis has been previously reported in gastric carcinoma (Ogawa et
al, 1997). It is striking that we found no intrahepatic metastasis in
17 HCCs with no abnormality in either the p21WAF1/CIP1 or the p53
protein, and that all HCCs with intrahepatic metastasis had altered
expression of p21WAF1/CIP1, p53, or both. These observations
strongly suggest that the p53–p21WAF1/CIP1 cell-cycle-regulating
pathway may play an important role in suppressing tumour
metastasis in HCCs.
We previously showed that other CDK inhibitors, p16INK4 (Hui
et al, 1996b) and p27Kip1 (Hui et al, 1998), are involved in hepato-
carcinogenesis. p16INK4, p21WAF1/CIP1 and p27Kip1 appear to be
independently inactivated and dysfunction of CDK inhibitors is a
very common event in HCCs (Hui et al, 1996a, 1998; Hui and
Makuuchi, 1999). Understanding the mechanisms that inactivate
these CDK inhibitors may be important for seeking new biological
therapies for HCCs.
In conclusion, our present study has shown that: (1) absence of
p21WAF1/CIP1 expression is very common in HCCs; (2) p21WAF1/CIP1 is
probably regulated via different pathways in HCCs differing in
their hepatitis viral infection status, and p21WAF1/CIP1 expression
appears to be predominantly related to altered p53 in HCV-related
HCCs; (3) in addition to p53-dependent transcriptional regulation,
HCV core protein suppression of the transcriptional activity of the
p21WAF1/CIP1 promoter and post-transcriptional regulation are alter-
nate pathways by which p21WAF1/CIP1 expression can be down-regu-
lated; (4) disruption of the p53–p21WAF1/CIP1 cell-cycle-regulating
pathway may contribute to malignant progression of HCC.
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